Efficacy, safety and tolerability of combined low-dose simvastatin-fenofibrate treatment in primary mixed hyperlipidaemia (Q80378922)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17523707%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

title

Efficacy, safety and tolerability of combined low-dose simvastatin-fenofibrate treatment in primary mixed hyperlipidaemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17523707%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

C Stefanutti

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17523707%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

A Bucci

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17523707%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

S Di Giacomo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17523707%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

N Fraone

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17523707%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

A Pace

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17523707%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

M Mareri

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17523707%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

A Musca

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17523707%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

A Mammarella

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17523707%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

publication date

1 January 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17523707%20AND%20SRC:MED&resulttype=core&format=json

Clinical Drug Investigation

31 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17523707%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17523707%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

465-477

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17523707%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17523707%20AND%20SRC:MED&resulttype=core&format=json

Serum lipid comparison in patients treated by statins or fibrates: existence of bad HDL-C responders to statins

31 December 2019

cites work

1 reference

12 December 2020

The Münster Heart Study (PROCAM): total mortality in middle-aged men is increased at low total and LDL cholesterol concentrations in smokers but not in nonsmokers

1 reference

12 December 2020

Clinical pharmacokinetics of fibric acid derivatives (fibrates).

1 reference

12 December 2020

Fenofibrate plus simvastatin therapy versus simvastatin plus cholestyramine therapy for familial hypercholesterolaemia

1 reference

12 December 2020

An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines. National Cholesterol Education Program

1 reference

12 December 2020

Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia

1 reference

12 December 2020

Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate.

1 reference

12 December 2020

Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates

1 reference

12 December 2020

Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia

1 reference

12 December 2020

Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin Study Group

1 reference

12 December 2020

Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group

1 reference

12 December 2020

Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III

1 reference

12 December 2020

Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors

1 reference

12 December 2020

Combination drug therapy for dyslipidemia.

1 reference

12 December 2020

Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia

1 reference

12 December 2020

Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety

1 reference

12 December 2020

The fibrates in clinical practice: focus on micronised fenofibrate

1 reference

12 December 2020

Effectiveness and safety of alternate-day simvastatin and fenofibrate on mixed hyperlipidemia

1 reference

12 December 2020

Comparison of the efficacy and safety of fenofibrate and lovastatin in patients with primary type IIa or IIb hyperlipidaemia

1 reference

12 December 2020

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

12 December 2020

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

12 December 2020

Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia.

1 reference

12 December 2020

FDA adverse event reports on statin-associated rhabdomyolysis

1 reference

12 December 2020

Evaluation of the synergistic adverse effects of concomitant therapy with statins and fibrates on rhabdomyolysis

1 reference

12 December 2020

The role of fibric acids in atherosclerosis

1 reference

12 December 2020

Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations

1 reference

12 December 2020

Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study

1 reference

12 December 2020

Effects of fibrates on metabolism of statins in human hepatocytes

1 reference

12 December 2020

Overview of fenofibrate

1 reference

12 December 2020

Fibrates, dyslipoproteinaemia and cardiovascular disease

1 reference

12 December 2020

Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome

1 reference

12 December 2020

Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group.

1 reference

12 December 2020

Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment

1 reference

12 December 2020

Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III.

1 reference

12 December 2020

Pancreatitis associated with simvastatin plus fenofibrate

1 reference

12 December 2020

Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins

1 reference

12 December 2020

Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia

1 reference

12 December 2020

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia

1 reference

12 December 2020

10.2165/00044011-200424080-00005

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17523707%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference